Back to Leadership

Robert J. Hombach

  • Director, Aptinyx Inc; Director, Embecta Corporation


  • Audit
  • Compensation


Robert J. Hombach joined BioMarin’s Board of Directors in September 2017 and currently serves as Chair of the Audit Committee.

Mr. Hombach served as Executive Vice President, Chief Financial Officer and Chief Operations Officer of Baxalta Inc., until it was acquired by Shire plc, in June 2016. Baxalta was spun off from its parent, Baxter International Inc. in July 2015, where Mr. Hombach served as Vice President and Chief Financial Officer from June 2010 until the Baxalta spin-off. Prior to the Baxalta spin off, Mr. Hombach served in a number of senior finance positions at Baxter, including Chief Financial Officer.

Mr. Hombach currently serves on the board of Embecta Corporation. Previously, Mr. Hombach served on the boards of Aptinyx Inc. from May 2018 to June 2023, CarMax, Inc. from April 2018 to June 2022, and Naurex, Inc., which was acquired by Allergan in August 2015.

Mr. Hombach holds an M.B.A. from Northwestern University’s J.L. Kellogg Graduate School of Management and a B.S. in Finance cum laude from the University of Colorado.